Skip to Main Content
Table 1.

Patient characteristics

Age/GenderPrimary tumorPrior treatment in chronological order (no. cycles)
Group A (23 patients): vinblastine, cyclophosphamide, and rofecoxib   
59/M Rectum FUFA (×5), raltitrexed (×5) 
24/F Hodgkin's disease ABVD (×6), DHAP (×2), cyclophosphamide, carmustine, etoposide (×1) 
70/F Breast CMF (×6) 
77/F Rectum FUFA (×1), raltitrexed (×6), irinotecan (×2) 
55/M Hodgkin's disease ABVD (epirubicin used) (×6), DHAP (×3) 
67/M Lung Vinorelbine/cisplatinum (×7), carboplatin (×1) 
53/M Melanoma (cutaneous) None 
63/M Colon FUFA (×6), IFL (×5) 
65/F Renal cell IFN (×2) 
60/M Gastric non–Hodgkin's lymphoma CHOP (×6), ICE (×4), ESHAP (×4), CHOP (×2) 
72/M Non–Hodgkin's lymphoma CHOP (epirubicin used) (×8) 
69/M Colon IFL (×2) 
79/F Liver Doxorubicin (×6) 
52/F Ovary Paclitaxel/cisplatin (×5) 
34/M Hodgkin's disease ABVD (×6), mini-BEAM, etoposide (×2) 
56/F Endometrium None 
72/F Breast Epirubicin (×12), CMF (×9) 
63/F Leiomyosarcoma Doxorubicin (×1) 
74/F Endometrium Paclitaxel/carboplatin (×5) 
65/F Ovary Paclitaxel/cisplatin (×6), paclitaxel/carboplatin (×6), carboplatin (×3) 
46/M Colon FUFA (×6), IFL (×5) 
61/M Endometrium None 
55/M Rectum FUFA (×12), IFL (×6) 
Group B (24 patients): vinblastine, cyclophosphamide, rofecoxib, and minocycline   
63/M Pancreas Gemcitabine (×8) 
65/F Rectosigmoid IFL (×6) 
56/F Cholangiocarcinoma ECF (×6) 
70/M Colon IFL (×2) 
60/M Colon FUFA (×6), CONT FU (×2), irinotecan (×1) 
78/M Rectum FUFA (×17), irinotecan (×4), CONT FU (×3) 
61/M Colon FUFA (×11), capecitabine (×3) 
69/M Pancreas None 
71/F Endometrium None 
43/M Pancreas Gemcitabine (×3) 
62/M Rectosigmoid FUFA (×14), irinotecan (×13), capecitabine (×6) 
58/F Ovary Paclitaxel/cisplatin (×6), carboplatin\cyclophosphamide (×3), topotecan (×9), doxorubicin (×3) 
65/M Colon IFL (×2), FOLFOX4 (×6) 
59/F Breast Paclitaxel (×2), FAC (×6), MMM (×5) 
69/F Pancreas None 
70/F Peritoneum Paclitaxel/carboplatin (×6), topotecan (×2) 
56/F Ovary Paclitaxel/carboplatin (×6), topotecan (×4) 
49/M Colon IFL (×4), FOLFOX4 (×12) 
42/F Breast AC (×4), CMF (×5), docetaxel (×4), docetaxel/xeloda (×6) 
34/M Spindle cell sarcoma* CHOP (×2), ICE (×1) 
60/M Pancreas Gemcitabine (×8) 
49/F Lung Vinorelbine/cisplatinum (×2), docetaxel (×4) 
60/F Breast CEF (×1), FAC (×6), docetaxel (×6) 
76/F Endometrium None 
Age/GenderPrimary tumorPrior treatment in chronological order (no. cycles)
Group A (23 patients): vinblastine, cyclophosphamide, and rofecoxib   
59/M Rectum FUFA (×5), raltitrexed (×5) 
24/F Hodgkin's disease ABVD (×6), DHAP (×2), cyclophosphamide, carmustine, etoposide (×1) 
70/F Breast CMF (×6) 
77/F Rectum FUFA (×1), raltitrexed (×6), irinotecan (×2) 
55/M Hodgkin's disease ABVD (epirubicin used) (×6), DHAP (×3) 
67/M Lung Vinorelbine/cisplatinum (×7), carboplatin (×1) 
53/M Melanoma (cutaneous) None 
63/M Colon FUFA (×6), IFL (×5) 
65/F Renal cell IFN (×2) 
60/M Gastric non–Hodgkin's lymphoma CHOP (×6), ICE (×4), ESHAP (×4), CHOP (×2) 
72/M Non–Hodgkin's lymphoma CHOP (epirubicin used) (×8) 
69/M Colon IFL (×2) 
79/F Liver Doxorubicin (×6) 
52/F Ovary Paclitaxel/cisplatin (×5) 
34/M Hodgkin's disease ABVD (×6), mini-BEAM, etoposide (×2) 
56/F Endometrium None 
72/F Breast Epirubicin (×12), CMF (×9) 
63/F Leiomyosarcoma Doxorubicin (×1) 
74/F Endometrium Paclitaxel/carboplatin (×5) 
65/F Ovary Paclitaxel/cisplatin (×6), paclitaxel/carboplatin (×6), carboplatin (×3) 
46/M Colon FUFA (×6), IFL (×5) 
61/M Endometrium None 
55/M Rectum FUFA (×12), IFL (×6) 
Group B (24 patients): vinblastine, cyclophosphamide, rofecoxib, and minocycline   
63/M Pancreas Gemcitabine (×8) 
65/F Rectosigmoid IFL (×6) 
56/F Cholangiocarcinoma ECF (×6) 
70/M Colon IFL (×2) 
60/M Colon FUFA (×6), CONT FU (×2), irinotecan (×1) 
78/M Rectum FUFA (×17), irinotecan (×4), CONT FU (×3) 
61/M Colon FUFA (×11), capecitabine (×3) 
69/M Pancreas None 
71/F Endometrium None 
43/M Pancreas Gemcitabine (×3) 
62/M Rectosigmoid FUFA (×14), irinotecan (×13), capecitabine (×6) 
58/F Ovary Paclitaxel/cisplatin (×6), carboplatin\cyclophosphamide (×3), topotecan (×9), doxorubicin (×3) 
65/M Colon IFL (×2), FOLFOX4 (×6) 
59/F Breast Paclitaxel (×2), FAC (×6), MMM (×5) 
69/F Pancreas None 
70/F Peritoneum Paclitaxel/carboplatin (×6), topotecan (×2) 
56/F Ovary Paclitaxel/carboplatin (×6), topotecan (×4) 
49/M Colon IFL (×4), FOLFOX4 (×12) 
42/F Breast AC (×4), CMF (×5), docetaxel (×4), docetaxel/xeloda (×6) 
34/M Spindle cell sarcoma* CHOP (×2), ICE (×1) 
60/M Pancreas Gemcitabine (×8) 
49/F Lung Vinorelbine/cisplatinum (×2), docetaxel (×4) 
60/F Breast CEF (×1), FAC (×6), docetaxel (×6) 
76/F Endometrium None 

Abbreviations: FU, 5-fluorouracil; ABVD, adriamycin (doxorubicin), bleomycin, vinblastine, DTIC (dacarbazine); AC, adriamycin (doxorubicin), cyclophosphamide; BEAM, BCNU (carmustine), etoposide, cytarabine, and melphalan; CEF, cyclophosphamide, epirubicin, fluorouracil; CHOP, cyclophosphamide, adriamycin (doxorubicin), vincristine, prednisone; CMF, cyclophosphamide, methotrexate, fluorouracil; DHAP, dexamethasone, ara-C (cytarabine), cisplatin; ECF, fluorouracil, epirubicin, cisplatin; ESHAP, etoposide, solumedrol, cytosine arabinoside, cisplatin; FAC, fluorouracil, adriamycin (doxorubicin), cyclophosphamide; FOLFOX4, oxaliplatin, leucovorin, fluorouracil; FUFA, fluorouracil, leucovorin; IFL, bolus FU/leucovorin, irinotecan; MMM, methotraxate, mitomycin c, mitoxantrone.

*

Initially diagnosed as anaplastic non–Hodgkin's lymphoma.

Close Modal

or Create an Account

Close Modal
Close Modal